- Severe disorders with devastating and life-threatening medical consequences
- Disorders with ineffective, or no treatment options
- Disorders that are ultra-rare and affect very small numbers of patients
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.
Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.
Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.